Vividion Therapeutics Inc. has disclosed VVD-065, a novel, first-in-class, allosteric molecular glue of the KEAP1-CUL3 E3-ligase complex, for the potential treatment of NRF2-activated cancers. NRF2 (nuclear factor erythroid 2-related factor 2) is a significant mediator of antioxidant response.
Researchers from Biolexis Therapeutics Inc. presented the development of a potent and highly selective CDK9 inhibitor, BLX-3030, and its analogues for the treatment of N-Myc and c-Myc-driven cancers.
Researchers from Generate Biomedicines Inc. have detailed the discovery and preclinical characterization of GB-0669, a spike S2-targeted monoclonal antibody (MAb) being developed for the prophylaxis of SARS-CoV-2 infection. Machine learning models were used to identify MAbs targeting the conserved S2 stem helix and RBD class IV region of spike.
Researchers from Astellas Pharma Inc. presented preclinical data for the novel small-molecule diacylglycerol kinase ζ (DGKζ) inhibitor ASP-1570, currently in phase I development for the treatment of solid tumors (NCT05083481).
KRAS is a GTP-binding protein involved in cell growth control that requires post-translational farnesylation to be active. KRAS G12D mutations are mostly associated with pancreatic, colorectal and non-small-cell lung cancers and occur less commonly in other cancers. There are currently no therapies approved to specifically target this mutation.
At the IDWeek 2023 infectious disease conference held last week in Boston, fungal infections got the audience’s attention during the session titled, “The antifungal evolution: novel strategies for a changing world.” With the emergence of some resistant pathogens such Candida auris and the growing disease burden in the population at risk for life-threatening fungal infections, these pathogens are more than ever standing out within the infectious diseases arena.
New and updated preclinical data presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference in Boston, by: Astrazeneca, Boundless Bio, Corbus Pharmaceuticals, Fusion Pharmaceuticals, Phio Pharmaceuticals, Scorpion Therapeutics.
Researchers from Shanghai Jiao Tong University and affiliated organizations presented data from a study that aimed to identify new pathogenic genes for autosomal dominant hypotrichosis (hair loss).
Apogee Therapeutics Inc. recently presented preclinical data on its lead candidate, APG-777, a fully optimized and half-life extended antibody targeting IL-13 for the treatment of atopic dermatitis and asthma.
RSS
